Literature DB >> 31097634

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Frédéric Baron1, Fabio Efficace2, Laura Cannella2, Roel Willemze3, Marco Vignetti2, Petra Muus4,5, Jean-Pierre Marie6, Dario Ferrero7, Paola Fazi2, Edoardo La Sala2, Jean-Henri Bourhis8, Francesco Fabbiano9, Alberto Bosi10, Marco Sborgia11, Giovanni Martinelli12, Sebastian Wittnebel13, Silvia Trisolini14, Maria Concetta Petti14, Constantijn J M Halkes3, Walter J F M van der Velden4, Theo de Witte4, Sergio Amadori15, Robert A Zittoun6, Stefan Suciu16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31097634      PMCID： PMC6939505          DOI： 10.3324/haematol.2019.221333

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.

Authors:  Maximilian Christopeit; Myriam Labopin; Norbert-Claude Gorin; Francesco Saraceni; Jakob Passweg; Edouard Forcade; Johan Maertens; Maria Teresa Van Lint; Alberto Bosi; Dietger Niederwieser; Gerhard Ehninger; Emmanuelle Polge; Mohamad Mohty; Arnon Nagler
Journal:  Am J Hematol       Date:  2018-10-26       Impact factor: 10.047

2.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Authors:  Jan J Cornelissen; Wim L J van Putten; Leo F Verdonck; Matthias Theobald; Emanuel Jacky; Simon M G Daenen; Marinus van Marwijk Kooy; Pierre Wijermans; Harry Schouten; Peter C Huijgens; Hans van der Lelie; Martin Fey; Augustin Ferrant; Johan Maertens; Alois Gratwohl; Bob Lowenberg
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Authors:  M Hengeveld; S Suciu; Y Chelgoum; J-P Marie; P Muus; F Lefrère; F Mandelli; F Pane; S Amadori; G Fioritoni; B Labar; F Baron; J Cermak; J-H Bourhis; G Storti; P Fazi; A Hagemeijer; M Vignetti; R Willemze; T de Witte
Journal:  Bone Marrow Transplant       Date:  2014-11-17       Impact factor: 5.483

5.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Authors:  John R Wingard; Navneet S Majhail; Ruta Brazauskas; Zhiwei Wang; Kathleen A Sobocinski; David Jacobsohn; Mohamed L Sorror; Mary M Horowitz; Brian Bolwell; J Douglas Rizzo; Gérard Socié
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

6.  Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.

Authors:  Y Beguin; B Sautois; P Forget; J Bury; G Fillet
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

7.  Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.

Authors:  Andrew D Chantry; John A Snowden; Charles Craddock; Karl Peggs; Claire Roddie; Jenny I O Craig; Kim Orchard; Keiren E Towlson; Rachel M Pearce; David I Marks
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

8.  Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission.

Authors:  Norbert-Claude Gorin; Myriam Labopin; Didier Blaise; Josy Reiffers; Giovanna Meloni; Mauricette Michallet; Theo de Witte; Michel Attal; Bernard Rio; Francois Witz; Loic Fouillard; Roel Willemze; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

9.  Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT.

Authors:  Norbert Claude Gorin; Myriam Labopin; Didier Blaise; Pierre-Yves Dumas; Thomas Pabst; Silvia Maria Trisolini; William Arcese; Mohamed Houhou; Mohamad Mohty; Arnon Nagler
Journal:  Am J Hematol       Date:  2018-04-28       Impact factor: 10.047

Review 10.  Hematopoietic stem cell transplantation for patients with AML in first complete remission.

Authors:  Jan J Cornelissen; Didier Blaise
Journal:  Blood       Date:  2015-12-10       Impact factor: 22.113
View more
  4 in total

1.  Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT.

Authors:  Frédéric Baron; Myriam Labopin; Didier Blaise; Maija Itälä-Remes; Gérard Socié; Edouard Forcade; Ibrahim Yakoub-Agha; Norbert Claude Gorin; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-09-04       Impact factor: 5.483

2.  Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.

Authors:  Safaa M Ramadan; Stefan Suciu; Marian J P L Stevens-Kroef; Roelof Willemze; Sergio Amadori; Theo de Witte; Bob Löwenberg; Petra Muus; Boris Labar; Liv Meert; Gaetan de Schaetzen; Giovanna Meloni; Giuseppe Leone; Marco Vignetti; Jean-Pierre Marie; Michael Lübbert; Frédéric Baron
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

3.  Comparison of post-remission strategies in acute myeloid leukemia: Autologous hematopoietic stem cell transplantation versus consolidation chemotherapy.

Authors:  Zeynep Arzu Yegin; Asena Dikyar; Lale Aydın Kaynar; Ferda Can; Zübeyde Nur Özkurt; Münci Yağcı
Journal:  Hematol Rep       Date:  2020-12-02

4.  Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores.

Authors:  Adrien De Voeght; Evelyne Willems; Sophie Servais; Laurence Seidel; Michelle Pirotte; Paul Massion; Nathalie Layios; Maguy Pereira; Benoit Misset; Jean-Luc Canivet; Yves Beguin; Frédéric Baron
Journal:  Cancers (Basel)       Date:  2022-08-31       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.